Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

linde medicale srl - aria medicale - aria medicale

Italia - italiano - Ministero della Salute

precision medical, inc. - sistemi gas medicali/medicinali e relativi componenti accessori

Italia - italiano - Ministero della Salute

precision medical, inc. - sistemi gas medicali/medicinali e relativi componenti accessori

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

b. braun melsungen ag - paracetamolo - paracetamolo

Unione Europea - italiano - EMA (European Medicines Agency)

amgen europe b.v. - blinatumomab - linfoma di leucemia linfoblastica a cellule precursori - agenti antineoplastici - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

b. braun melsungen ag - solventi e diluenti, comprese le soluzioni detergenti - solventi e diluenti, comprese le soluzioni detergenti

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

b. braun melsungen ag - levulosio soluzioni - levulosio soluzioni

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

b. braun melsungen ag - granisetron - granisetron

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - glucosio - soluzione per infusione - glucosum 50 g ut glucosum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. corresp. 837 kj. - calorie e acqua - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

b. braun medical ag - glucosio - soluzione per infusione - glucosum 100 g ut glucosum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. corresp. 1670 kj. - calorie e acqua - synthetika